TNF and chronic myelogenous leukemia, BCR-ABL1 positive: Pretreatment with compounds 1, 2, 3, 5, 6, 8, 9, 10, 11, 12, and 13 resulted in significant suppression of CML-AGE-mediated upregulation of Tnfa mRNA; p < 0.05 (Fig. 6a); and pretreatment with all compounds 1–13 resulted in significant suppression of Il6 mRNA versus vehicle in the kidney after injection of RAGE ligand, CML-AGE; p < 0.05 (Fig. 6b).